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Abstract
Background. Clinical and experimental evidence
suggest that haemodialysis (HD) procedure is an
inflammatory process. For the production of pro-
inflammatory lipid mediators in many inflamma-
tory reactions, the release of arachidonic acid by
phospholipase A2 (PLA2) enzyme is a prerequisite.
Therefore, the purpose of the present investigation was
to establish whether the activity of PLA2 increases
during HD and whether the increase depends on the
type of dialyser used.
Methods. We performed dialysis in eight chronic HD
patients. Blood samples entering and leaving the dia-
lyser were obtained before and at 15, 60, 120 and 180
min after the dialysis was started, on one occasion
using a cuprophane and on another occasion a cellulose
triacetate dialyser. PLA2 activity was assessed in crude
plasma and in plasma extract.
Results. PLA2 activity in plasma extract exhibited sim-
ilar biochemical properties to that of inflammatory
human synovial fluid PLA2 enzyme which is of group
II PLA2. PLA2 activity in crude plasma represents a
type of PLA2 other than the synovial type. In HD
patients, baseline PLA2 activities in crude plasma and
plasma extract were significantly increased when com-
pared to normal subjects. An increase in PLA2 activity
was observed in crude plasma with a peak appearing
at 15 min when the patients were dialysed with cupro-
phane and cellulose triacetate membranes. This
increase was observed in both arterial and venous
blood samples and was more pronounced when the
patients were dialysed with cuprophane than with
cellulose triacetate membranes. When PLA2 was
assessed in plasma extract, the activity increased only
with cuprophane but not with cellulose triacetate
membranes.
Conclusion. PLA2 activity in plasma is increased in
HD patients and increases during the dialysis proced-
ure to a greater extent with a less biocompatible
membrane. Continuous activation of PLA2 might be
relevant for long-term deleterious consequences of HD.
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Introduction
Haemodialysis in humans and in experimental animals
may result in adverse anaphylactic symptoms such as
hypotension, respiratory distress, oedema of the skin,
muscle cramps, nausea, headache, diaphoresis, feeling
of fatigue, and lack of energy [1-3]. Some of these
symptoms are used as clinical endpoints to assess acute
side-effects due to the methods and materials used
during dialysis [ 1 ]. One of the major cause for anaphyl-
actic symptoms has been ascribed to the bioincompat-
ibility of the blood/membrane contact [4-6]. For
bioincompatibility, the cellulosic nature of the mem-
branes has been implicated. In different membranes
the cellulose has been treated differently or different
cellulose material has been used to form porous
membranes. These membranes are treated with copper
and ammonia in cuprophane membranes, whereas
acetylated cellulose (CT 110, CT 190, Baxter, IL, USA)
or saponified cellulose ester (135 see, C-D Medical)
are used in other membranes. Cellulose is regenerated
by removing acetate moities and other chemicals. In
cellulose acetate membranes the acetate moities are
retained [7]. The use of these membranes is associated
with a variable incidence of side-effects. Compared to
other membranes, cuprophane membranes are consid-
ered to be less biocompatible [4-11].
As a result of blood/membrane interaction several
studies reported leukopenia due to complement activa-
tion [2,8], increased production of |32-microglobulin
[12], interleukin-1 (IL-1), interleukin-6(IL-6), tumour
necrosis factor (TNF) [9-11,13,14], prostacyclin,
thromboxane, platelet activating factor (PAF), hydro-
xyeicosatetraenoic acids (HETS) [9,15-17] during
haemodialysis. Many inflammatory cells release prosta-
glandins and thromboxanes in situ with cuprophane
membranes [9]. Proinflammatory autacoids like pros-
taglandin, prostacyclin, thromboxanes, PAF, HETS
are the metabolites of free arachidonic acid. Free
arachidonic acid is primarily released by phospholipase
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A2 (PLA2) enzyme from phospholipids by hydrolysing
a fatty acyl ester bond at sn-2 position [18]. PLA2
enzyme is activated by endotoxins and cytokines like
interleukins and TNF [19-21]. Thus activation of
PLA2 during haemodialysis might account for some of
the clinical signs and symptoms during dialysis.
Therefore we investigated the impact of dialysis on the
activation of PLA2 in vivo by comparing the effect of
a membrane considered to be rather bioincompatible
with that of a biocompatible one.
Subjects and methods
Subjects and study design
Eight haemodialysis (HD) patients (4 males and 4 females)
gave their written consent to participate in the following
study which was approved by the ethical committee of the
Inselspital, University of Bern. Their age ranged from 24 to
67 years (mean age 44.5 years). Eight healthy volunteers
matched for age and sex with the HD patients (4 males and
4 females; range of age 26-64 years, mean age 45 years) were
used for comparison of baseline PLA2 activity before the
dialysis was started. All HD patients had a history of at least
6 months on haemodialysis treatment and were undergoing
haemodialysis regularly twice or three times a week using
bicarbonate dialysate. These HD patients had the following
underlying diseases causing endstage renal failure: pyelo-
nephritis (4 patients), glomerulonephritis (3 patients) and
autosomal dominant polycystic kidney disease (1 patient).
No medication known to interfere with PLA2 activity were
taken either by the patients or by the volunteers.
The patients were routinely dialysed with a cellulose triacet-
ate hollow-fibre dialyser (CT 110, Baxter, IL, USA). For the
study day, in addition a less biocompatible filter with a
similar surface area was used for comparison (Cuprophan
capillary dialyser, Hemoflow E4S, Fresenius). Dialysis was
performed by puncturing a-v fistulas at the forearm with a
15-G needle. The first blood sample was collected before
dialysis treatment. Additional blood samples were obtained
either from the blood line coming directly from the body
('arterial') or from the blood line coming from the dialyser
('venous') at the following time points: 15 min after bolus
injection of heparin (3000 U), 60 min and 120 min thereafter,
and at the end of dialysis (— 180 min).
To study the effect of heparin, two patients were dialysed
using cellulose triacetate hollow-fibre dialyser and with cup-
rophane capillary dialyser without administering any heparin.
Arterial blood samples were collected at the start of dialysis
and at 15 min on dialysis. The dialysis was later on continued
by administering heparin.
Analytical procedures
Blood collection and preparation of crude plasma. Four milli-
litres of whole blood was collected using 4-ml Monovette
K.E tubes containing 1.6 mg EDTA/ml blood (Sarstedt,
Neumbrecht Germany). Within 30 min the blood samples
were centrifuged at 3000 g for 10 min. The upper cell free
plasma was carefully collected and stored at — 20"C until
further use.
Extraction of plasma for PLA2 activity measurements. Crude
plasma (750 ul) was extracted with equal volumes of 0.36 N
sulphuric acid and was kept on ice water for 60 min. The
sulphuric acid was removed by dialysing (membrane with a
molecular weight cut-off of 6000-8000 daltons) against
10 mM sodium acetate buffer pH 4.5. The dialysed plasma
sample was incubated for 30 min at 80°C, which resulted in
the formation of a white precipitate. This precipitate was
resuspended in 10 mM sodium acetate pH 4.5 to a final
volume of 5 ml. This sample was centrifuged at 20 000 g for
30 min. The supernatant was separated and stored at — 20°C
until further use. This supernatant is designated below as
'plasma extract'.
In-vitro effect of heparin on plasma PLA2 activity. Crude
plasma was mixed with indicated concentrations of heparin
and PLA2 activity was measured in crude plasma directly or
in the plasma extract.
Determination of protein concentrations. Protein concentra-
tions in crude plasma and in the plasma extracts were
determined using the bicinchonic acid protein assay reagent
(Pierce Chemical Co., Rockford, IL, USA).
Assay of PLA2 activity. [3H]-oleic-acid-(specific activity
lOCi/mmol, Amersham International pic. Buckinghamshire,
UK)-labelled Escherichia coli was prepared according to the
procedure of Patriarca et al. [22]. PLA2 activity in the crude
plasma and in the plasma extract was assayed using
[3H]-oleate-labelled, autoclaved E. coli as the substrate [23].
The reaction mixture 350 ul contained 100 mM Tris-HCl
pH 7.3/8.0 or sodium acetate buffer pH 6.0; 5 mM Ca2 + ,
2.85 x 108 cells of autoclaved E. coli cells (corresponding to
10000c.p.m. and 5.5 nmol lipid phosphorus). The amount
of protein was chosen such that 6-15% hydrolysis of substrate
was obtained when incubated at 37°C for 120 min. The
reaction was terminated by adding 100 (il of 2 N hydrochloric
acid. 100 ul of fatty acid-free BSA (100 mg/ml) was added,
and the tubes were vortexed and centrifuged at 13000g for
5 min. An aliquot (140 JJ.1 ) of the supernatant containing
released [3H]-oleic acid was mixed with scintillation cocktail
(Dynagel, J. T. Baker, B. V. Deventer, Holland) and counted
in a liquid scintillation counter. This method was further
characterized for the hydrolysis products in the supernatant
by extracting the fatty acids by the method of Bligh and
Dyer [24]. The extracted products were separated on silicagel
TLC plates (Merck, Basel, Switzerland) using the solvent
system petroleum ethendiethyl ethenacetic acid (80:20:3 by
v/v). Arachidonic acid (Sigma Chemie, Buchs, Switzerland)
was used as a standard. The specificity of this assay method
using E. coli as substrate was also characterized using
phospholipase C (PLC) and phospholipase D (PLD)
enzymes (Sigma Chemie, Buchs, Switzerland) using the same
condition as described for PLA2 assay. The released fatty
acids were analysed by fatty acid entrapment with fatty acid
free BSA as well as by separation on silica gel TLC plates
as described above after extraction by the method of Bligh
and Dyer [24].
Calculations and statistical analysis
The area under the activity of PLA2 versus time curve(AUC) from plasma samples was calculated by the linear
trapezoidal rule [25]. The values are expressed as mean
(±SD). The significance of differences was determined using
the Student t test for the paired observations or the
Wilcoxon test.
Results
PLA2 activity measured in the crude plasma and in
the plasma extract by the method using oleate labelled



























Fig. 1. Effect of pH (A) and calcium (B) on PLA2 enzyme activity in crude plasma ( , solid line and open symbols) and in plasma
extract ( , open line and closed symbols). Each value represents the average of three determinations. The buffers used were 100 mM
sodium acetate for pH 4.5-6.5 ( • ) ; 100 mM bis-tris for pH 6.5-7.0 (A); 100 mM HEPES for pH 7.0-7.5 ( • ) ; 100 mM tris-HCl for
pH 7.5-8.5 ( • ) and 100 mM glycyl-glycine for pH 8.5-9.5 (T) (optimum pH was measured in the presence of 5 mM calcium). The effect
of calcium concentrations on PLA2 activity in crude plasma ( , solid lines) and in plasma extract ( , open lines) was measured at
pH6.0(«)at pH8.5 (T).
E. coli as substrate showed specificity only for PLA2
enzyme. The measured radioactivity in the E. coli
supernatant was due to the release of free fatty acid
and not due to a mixture of hydrolysed fatty acids and
unhydrolysed E. coli phospholipids, as determined by
analysing the extracted lipids of the E. coli supernatant
on silica gel TLC plates (data not given). No free fatty
acids were measurable when PLC or PLD were used
instead of PLA2.
In order to define the optimum conditions for the
assessment of the PLA2 activity, the effect of variable
pH and calcium concentrations was determined. As
shown in Figure 1, PLA2 activity measured in crude
plasma and in plasma extract showed different bio-
chemical properties. In the presence of 5 mM Ca2+
PLA2 enzyme activity was optimal at pH 6.0 for crude
plasma, whereas in plasma extract the pH optimum
was shifted from the acidic to basic pH with a max-
imum activity at pH 8.0-9.0 (Figure 1A). PLA2
enzyme in the plasma extract was resistant to heat
(80°C for 30 min). Based on this analysis the following
conditions were chosen for all subsequent measure-
ments: In the presence of 5 mM Ca2+ crude plasma
was measured at pH 6.0 and plasma extract at pH 8.0.
PLA2 activity in crude plasma and in plasma extract
was also measured at a physiological pH of 7.3.
In all eight HD-patients the basal PLA2 activity was
higher than the corresponding activity from their
matched controls, when PLA2 was assessed in crude
plasma (/5<0.001) (Figure 2). The mean (±SD)
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Fig. 2. PLA2 activity in plasma samples from HD-patients before
dialysis and in control subjects. Open circles represent females and
closed squares represent males. The individual values of all subjects
and the mean values (bars) are shown. Matched controls had lower
PLA2 activity than HD-patients when measured in crude plasma(/>< 0.001) and in plasma extract I
9.95 +1.97 nmol fatty acid/ml/60 min and
3.93 ± 1.7 nmol fatty acid/ml/60 min respectively. The
corresponding values for PLA2 activity in plasma
extract were 5.5 ± 1.6 nmol fatty acid/ml/60 min
and 4.5+ 1.4 nmol fatty acid/ml/60 min respectively
(Figure 2). Six of eight HD-patients had higher PLA2
activity in plasma extract than their matched control
subjects (P<0.05). PLA2 activity was lower in plasma
extract than in crude plasma {P< 0.001) from patients,
but not from controls. Female HD patients and female
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controls had slightly higher PLA2 activities than males(Figure 2).
The activation of PLA2 during dialysis was assessed
in eight HD patients with a cuprophane filter and with
a cellulose triacetate filter (Figure 3). Measurements
were performed both in arterial and in venous blood.
PLA2 activities in crude plasma (Figure 3, A and B)
and in plasma extract (Figure 3, C and D) were
significantly increased in HD patients dialysed with
cuprophane filter compared to cellulose triacetate filter.
The increase in PLA2 activity is not due to haemocon-
centration because, all the patients were under steady
state and their protein levels in the samples did not
increase during dialysis (data not shown). In order to
get a quantitative estimate of the activation over time
the AUC was determined for each patient (Figure 4).
For each patient the AUC of the PLA2 activity was
calculated for venous and arterial blood while dialysed
with a cuprophane or with a cellulose triacetate mem-
brane. When the values derived from PLA2 measure-
ments in crude plasma were considered, each patient
had a higher AUC value in arterial and in venous
blood during dialysis with cuprophane than with
cellulose triacetate membranes (arterial, cuprophane
vs cellulose triacetate membrane 2243 ±404 vs
1756±320nmol fatty acid/ml/60 min, P< 0.001; ven-
ous, cuprophane vs cellulose triacetate membrane
3129 + 890 vs 2499 + 611 nmol fatty acid/ml/60 min,
P<0.001) (Figure 3 A and 3 B). Similarly the values
of PLA2 activity obtained from measurements in
plasma extracts from venous blood were higher in
eight of eight patients when cuprophane than when
cellulose triacetate membranes were used (1559 + 397
vs 997 ±340 nmol fatty acid/ml/60 min, P< 0.001
(Figure 3D). Seven of eight patients had higher AUCs
in plasma extracts from arterial blood when dialysed
with cuprophane than with cellulose triacetate
membranes (1713 ±436 vs 1035 ±472 nmol fatty
acid/ml/60 min P<0.02) (Figure 3C). PLA2 activity
measured at physiological pH in crude plasma and in
plasma extract also increased more, when the samples
were obtained during cuprophane than cellulose tri-
acetate membrane dialysis. Both plasma extract and
crude plasma showed a similar profile when determined
at pH 7.3 as measured at the optimal conditions (data
not shown).
For each individual the values of the AUC of PLA2
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Fig. 3. PLA2 activity measurements in crude plasma (A and B) and in plasma extract (C and D) before (0 min) and at several time points
during dialysis. The patients were dialysed with cuprophane ( • ) and cellulose triacetate (Z) membranes. Each value represents the mean
value (±SD) from eight patients.
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Fig. 4. The AUC of PLA2 activity was calculated for crude plasma and plasma extract in venous blood and plotted against the corresponding
AUC of PLA2 activity in arterial blood for each patient. The patients were dialysed using cuprophane ( • ) and cellulose triacetate
membranes (D). The oblique line is the line of identity. The activity measured in crude plasma was higher in venous blood than in arterial
blood (/><0.02), whereas no such difference was found for measurements of plasma extract.
and plasma extract were calculated. The individual
AUC value of the PLA2 activity of arterial blood was
plotted against the corresponding AUC value of the
PLA2 activity of venous blood (Figure 4). In crude
plasma 13 of 16 values were below the line of identity
indicating higher PLA2 activity in venous than in
arterial blood (/><0.02). In plasma extract the values
were randomly distributed on both sides of the line of
identity, indicating similar PLA2 activity in both arter-
ial and venous plasma extract.
Figure 5 depicts the effect of heparin on PLA2
activity in vitro. Heparin inhibited PLA2 activity in
crude plasma as well as in plasma extract when high
concentrations of heparin were used. During dialysis
the concentrations of heparin following an i.v. bolus












Fig. 5. In-viiro effect of heparin on PLA2 activity. Following the
addition of heparin (0.1, 0.5, 1.0, 2.0, and 10.0 units/ml) to plasma,
PLA2 activity was measured directly in crude plasma ( • ) and in
plasma extract (A). PLA2 activity was expressed asnmol fatty
acid/ml/60 min incubation. Each value represents the average of
three determinations.
per millilitre. To exclude the effect of heparin, in vivo
PLA2 activity was measured in two patients when
dialysed without heparin administration for 15 min.
Compared to zero min sample PLA2 activity measured
in crude plasma (at pH 6.0 or 7.3) and plasma extract
increased similarly after 15 min in both with and
without heparin administration (data not shown).
Discussion
PLA2 enzymes characterized so far are classified into
group I, II, III and IV based on their primary and
secondary structure [26,27]. PLA2 enzymes purified
from human platelets and from human synovial fluid
are classified under group II and are considered to
account for inflammatory reactions, whereas the
group I from pancreas appears not to be involved in
inflammation [28-30]. Group III enzyme has not been
detected in mammalians and the function of cytosolic
PLA2 (Group IV) is not very well defined yet [27].
Inflammatory human synovial fluid PLA2 (group II)
is resistant to low pH, optimally active in the presence
ofmM concentrations of calcium and at basic pH
[31,32]. PLA2 activity measured in plasma extract in
the present investigation exhibited similar biochemical/
biophysical properties as those known for PLA2
derived from inflammatory human synovial fluid PLA2.
The PLA2 assessed in crude plasma showed an
optimum activity at acidic pH. PLA2 activity measured
at pH 6.0 was abrogated when plasma was treated
with acid and heat suggesting that the activity meas-
ured in crude plasma represents a different type of
PLA2 than the synovial type (group II PLA2). A
similar pH optimum was observed by others in crude
plasma of uremic patients [33].
Before dialysis was started all patients received a
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bolus dose of heparin (~3000 U). When added in vitro
heparin inhibited PLA2 activity in crude plasma and
in plasma extract. This observation is in line with a
previous publication [33], but is at variance with an
observation made by Nakamura et ah, who showed
that heparin enhanced plasma PLA2 activity in patients
undergoing cardiac surgery [34]. Dialysis with and
without heparin administration resulted in a similar
increase in PLA2 activity. Thus, the increase in PLA2
activity during dialysis cannot be attributed to the
administered dose of 3000 U of heparin. Furthermore,
the increase in PLA2 activity in plasma cannot be
related to haemoconcentration because in all patients
ultrafiltration during dialysis was negligible as shown
by the absence of an increase in the concentrations of
plasma proteins.
When PLA2 activity was measured in crude plasma
the peak PLA2 activity was observed in all patients at
15 min after dialysis was started (Figure 3 A and B).
Previous investigations revealed similar peaks of biolo-
gical events during the initial 15 min on dialysis. These
changes comprise among others, a decline in the leuko-^
cyte count in peripheral blood, evidence for activation
of the complement system, release of TNF and interleu-
kins, including IL-ip and arachidonic acid metabolites,
such as PGE2, TXB2, PAF and HETS [2,8-17]. The
release of many arachidonic acid derivatives suggests
activation of PLA2, as shown by the present
investigations. The question arises what mediator(s)
activate (s) PLA2 activity during dialysis? Potential
candidates are TNF, possibly complement and IL-ip
[21,35]. IL-ip is a well established activator of group II
PLA2 [25]. Thus the link between IL-ip and PLA2
activity during dialysis is an attractive hypothesis.
However, in vivo this has to be considered carefully
for the following reasons.
In vitro studies clearly demonstrate that first, cyto-
kine releasing agents cross the membranes from the
dialysate to the blood side, second, complement factors
induced during blood contact with dialysis membranes
in vitro enhance transcription of IL-1 and third, cellu-
lose directly stimulates cytokine production [9,36,37].
Thus in-vitro data clearly support the hypothesis of
IL-1 to account for PLA2 activation. However, the in-
vivo observations are more difficult to reconcile with
that hypothesis, since only some [38-40] but not all
[41—43] studies reveal increased concentrations of
IL-1 P in blood. In line with our observation of a
more pronounced PLA2 activation possibly mediated
through IL-1 release with a more complement-
activating membrane is the recent report from
Schindler et ah [14] demonstrating an increased gene
expression of IL-1 (3 in peripheral blood mononuclear
cells leaving the dialyser 5 min after start of haemodia-
lysis. These authors found a significant correlation
between the increase in IL-ip mRNA and increase in
activated complement C5a. It is likely that IL-1 P
contributes significantly to the increase in PLA2 activ-
ity. However, it is open to speculation whether differ-
ential activation of IL-1 P by cuprophane and cellulose
triacetate membranes accounts for the differences in
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PLA2 activity observed during dialysis with these
two membranes. Note that no difference^ between
complement- and non-complement-activating mem-
branes has recently been found with respect to IL-1
release [38]. Besides differential activation of IL-1, a
different binding capacity of cuprophane and triacetate
membranes for PLA2 could also account for the differ-
ences in PLA2 increase.
The origin of the PLA2 in plasma is open to specula-
tion. We have recently shown that lung tissue exhibits
much higher activities of group II PLA2 than liver,
spleen, and kidney [28]. The lung is considered to
account for leukocyte sequestration during dialysis
[44]. It is conceivable that part of the activity of PLA2
in peripheral blood originates from lung tissue.
Alternatively activated and/or sequestered leukocytes
might account directly for the increase in PLA2 activity
[45,46]. The presence of PLA2 activity in granulocytes
and blood mononuclear cells was previously seen by
several groups [32,47] including our own (unpub-
lished data).
A higher PLA2 activity was measured in venous
than in arterial blood, when measurements were per-
formed in crude plasma (Figure 4), suggesting an
activation process or removal of an inhibitor by mem-
brane material. This venoarterial difference is in line
with the increased transcription of IL-ip in peripheral
blood mononuclear cells obtained from venous, but
not from arterial blood, as previously described by
Schindler et al. [14] and the increased production of
TXB2 in venous when compared with arterial blood
by Gawaz and Ward [16]. Interestingly the PLA2
activity in the plasma extract was the same in arterial
and venous blood (Figure 3C and D). PLA2 from
plasma extract (presumably group II) has different
biochemical properties than that measured in crude
plasma. Furthermore the regulation and tissue distribu-
tion of the PLA2 enzymes assessed in crude plasma
and plasma extract might be different and by that
explain the different behaviour with respect to the
activation during dialysis. With respect to the regula-
tion we and others have recently shown a differential
effect of glucocorticoids on group I and II PLA2 in
rats [28,29].
Recently PLA2 has been considered as a relevant
factor for another type of arthropathy, i.e. rheumatoid
arthritis [48]. High levels of PLA2 (presumably
group II) had been found in blood and synovial
fluid from these patients [49,50]. Injection of PLA2(group II) into animal joints resulted in a massive
inflammatory response with synovial cell swelling and
hyperplasia [51,52]. These changes eventually cause
periarticular subchondral bone erosions [53].
Periarticular erosions, albeit with a distinct distribution
from that in patients with rheumatoid arthritis, is a
feature of dialysis arthropathy [54-56]. It has been
suggested that dialysis arthropathy has an inflammat-
ory basis, since increased C-reactive protein concentra-
tions had been found in patients with dialysis
arthropathy [57]. Furthermore amyloid deposits con-
sisting of p2-microblobulin in joints and periarticular
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tissue were described in patients with dialysis arthropa-
thy [58]. The synthesis of pVmicroglobulin might
locally be increased by activation of mononuclear cells
[59] and by that mechanism favour p2-microglobulin
amyloid deposition in the presence of a decreased renal
clearance of that protein. Thus it is conceivable that
repeated PLA2 activation due to inflammatory effects
caused by extracorporeal circulation are relevant for
the understanding of some of these signs and symp-
toms, such as the pathogenesis of dialysis arthropathy.
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